CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases.


Journal

Minerva medica
ISSN: 1827-1669
Titre abrégé: Minerva Med
Pays: Italy
ID NLM: 0400732

Informations de publication

Date de publication:
Jun 2023
Historique:
medline: 14 6 2023
pubmed: 19 10 2022
entrez: 18 10 2022
Statut: ppublish

Résumé

Acute coronary syndromes (ACS) are a major cause of morbidity and mortality. As cytomegalovirus (CMV) may contribute to cardio-vascular (CV) manifestations, we sought to provide a proof-of-concept for the involvement of coronary and/or systemic CMV-reactivation as a possible ACS trigger. We prospectively enrolled consecutive patients undergoing a coronary angiography for ACS (acute-cases, N.=136), or non-ACS reasons (chronic-cases, N.=57). Matched coronary and peripheral blood-samples were processed for quantification of CMV-DNAemia (RT-PCR), CMV-IgG/IgM, and CMV-IgG avidity (ELISA). Peripheral-blood samples from 17 healthy subjects were included as controls. Out of the 193 cases included, 18.1% were aged ≤55 years, 92.5% were Central-European, and 100% immunocompetent. CMV-IgG seroprevalence was 91.7% (95%CI: 87.8-95.6), significantly higher than in healthy-controls (52.9% [95%CI: 29.2-76.5]; P<0.001), yet consistent across age-groups (P=0.602), male/females (P=0.765), and acute/chronic-cases (P=0.157). Median (IQR) IgG titers were 110 (84-163) AU/mL, with 0.62 (0.52-0.72) avidity, supporting a long history of infection. No acute CMV infections were found. In 22.6% (n/N.=40/177) of the IgG-positive cases low-level coronary and/or systemic CMV-DNAemia (always <40 copies/mL) was detected. While no differences in peripheral CMV-DNAemia prevalence were observed nor among cases nor controls, coronary CMV-DNAemia was more frequent in acute-cases without modifiable CV risk-factors (n/N.=4/10; 40.0%), than in chronic-cases (n/N.=6/55, 10.9%; P=0.029), or acute-cases with risk-factors (n/N.=16/112, 14.3%; P=0.058). CMV-IgG seroprevalence was high in patients with heart diseases. CMV-DNAemia can be found, although uncommonly, in coronary circulation during an ACS, with increased prevalence in older subjects and in absence of CV risk-factors, identifying possible areas for novel interventions.

Sections du résumé

BACKGROUND BACKGROUND
Acute coronary syndromes (ACS) are a major cause of morbidity and mortality. As cytomegalovirus (CMV) may contribute to cardio-vascular (CV) manifestations, we sought to provide a proof-of-concept for the involvement of coronary and/or systemic CMV-reactivation as a possible ACS trigger.
METHODS METHODS
We prospectively enrolled consecutive patients undergoing a coronary angiography for ACS (acute-cases, N.=136), or non-ACS reasons (chronic-cases, N.=57). Matched coronary and peripheral blood-samples were processed for quantification of CMV-DNAemia (RT-PCR), CMV-IgG/IgM, and CMV-IgG avidity (ELISA). Peripheral-blood samples from 17 healthy subjects were included as controls.
RESULTS RESULTS
Out of the 193 cases included, 18.1% were aged ≤55 years, 92.5% were Central-European, and 100% immunocompetent. CMV-IgG seroprevalence was 91.7% (95%CI: 87.8-95.6), significantly higher than in healthy-controls (52.9% [95%CI: 29.2-76.5]; P<0.001), yet consistent across age-groups (P=0.602), male/females (P=0.765), and acute/chronic-cases (P=0.157). Median (IQR) IgG titers were 110 (84-163) AU/mL, with 0.62 (0.52-0.72) avidity, supporting a long history of infection. No acute CMV infections were found. In 22.6% (n/N.=40/177) of the IgG-positive cases low-level coronary and/or systemic CMV-DNAemia (always <40 copies/mL) was detected. While no differences in peripheral CMV-DNAemia prevalence were observed nor among cases nor controls, coronary CMV-DNAemia was more frequent in acute-cases without modifiable CV risk-factors (n/N.=4/10; 40.0%), than in chronic-cases (n/N.=6/55, 10.9%; P=0.029), or acute-cases with risk-factors (n/N.=16/112, 14.3%; P=0.058).
CONCLUSIONS CONCLUSIONS
CMV-IgG seroprevalence was high in patients with heart diseases. CMV-DNAemia can be found, although uncommonly, in coronary circulation during an ACS, with increased prevalence in older subjects and in absence of CV risk-factors, identifying possible areas for novel interventions.

Identifiants

pubmed: 36255708
pii: S0026-4806.22.07778-3
doi: 10.23736/S0026-4806.22.07778-3
doi:

Substances chimiques

DNA 9007-49-2
Immunoglobulin G 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

289-299

Auteurs

Valeria Cento (V)

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy - valeria.cento@unimi.it.

Luna Colagrossi (L)

Unit of Microbiology and Diagnostic Immunology, Bambino Gesù Children's Hospital, Rome, Italy.

Irene Bossi (I)

A. De Gasperis Cardio Center, ASST Niguarda Hospital, Milan, Italy.

Daniele Armenia (D)

Saint Camillus International University of Health Sciences, UniCamillus, Rome, Italy.

Alice Nava (A)

Unit of Chemical-Clinical and Microbiological Analysis, ASST Niguarda Hospital, Milan, Italy.

Enrico Piccinelli (E)

A. De Gasperis Cardio Center, ASST Niguarda Hospital, Milan, Italy.

Alessandro Maloberti (A)

A. De Gasperis Cardio Center, ASST Niguarda Hospital, Milan, Italy.

Elvira Inglese (E)

Unit of Chemical-Clinical and Microbiological Analysis, ASST Niguarda Hospital, Milan, Italy.

Elisa Matarazzo (E)

Residency in Microbiology and Virology, University of Milan, Milan, Italy.

Federica DI Ruscio (F)

Residency in Microbiology and Virology, University of Milan, Milan, Italy.

Pierpaolo Paba (P)

Unit of Virology, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy.

Fabbio Marcuccilli (F)

Unit of Virology, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy.

Marco Perrone (M)

Unit of Cardiology, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy.

Gaetano Chiricolo (G)

Unit of Cardiology, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy.

Claudia Alteri (C)

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Francesco Scaglione (F)

Unit of Chemical-Clinical and Microbiological Analysis, ASST Niguarda Hospital, Milan, Italy.

Chiara Vismara (C)

Unit of Chemical-Clinical and Microbiological Analysis, ASST Niguarda Hospital, Milan, Italy.

Daniela A Campisi (DA)

Unit of Chemical-Clinical and Microbiological Analysis, ASST Niguarda Hospital, Milan, Italy.

Diana Fanti (D)

Unit of Chemical-Clinical and Microbiological Analysis, ASST Niguarda Hospital, Milan, Italy.

Francesco Romeo (F)

Unit of Cardiology, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy.

Massimo Andreoni (M)

Unit of Infectious Diseases, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy.

Fabrizio Oliva (F)

A. De Gasperis Cardio Center, ASST Niguarda Hospital, Milan, Italy.

Francesca Ceccherini-Silberstein (F)

Department of Experimental Medicine, Tor Vergata University, Rome, Italy.

Cristina Giannattasio (C)

A. De Gasperis Cardio Center, ASST Niguarda Hospital, Milan, Italy.

Carlo F Perno (CF)

Unit of Microbiology and Diagnostic Immunology, Bambino Gesù Children's Hospital, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH